Amarin Corporation and Biologix FZco have announced that the Saudi Food and Drug Authority has approved VASCEPA® (icosapent ethyl) capsules as an adjunct to statin therapy in adult patients with elevated triglycerides levels who are at high-risk of cardiovascular events due to established cardiovascular disease or diabetes mellitus and at least one other risk factor for cardiovascular disease. T..
Aisa Pharma has initiated the second part of its RECONNOITER Phase 2 study, which will evaluate Profervia®, an oral calcium-channel antagonist, in patients with systemic sclerosis and Raynaud's phenomenon. The double-blind, placebo-controlled, randomized, prospective crossover study is expected to last approximately 10 months. Aisa also presented positive safety and efficacy data from the Phase ..
Eloxx Pharmaceuticals, a leader in ribosomal RNA-targeted genetic therapies for rare diseases, has highlighted recent Alport syndrome natural history data presented at the 60th ERA (European Renal Association) Congress. The RaDaR natural history study indicates that patients with autosomal recessive COL4A4 mutations have the severest form of the disease, with a more rapid progression to kidney f..
Biomerica Inc. has received a Notice of Allowance for a patent application that covers a development stage IT system from the China National Intellectual Property Administration. The system includes an artificial intelligence claim aimed at assisting individuals to protect themselves against potential adverse reactions to specific food ingredients and offers personalized approaches to dietary in..
Jubilant Therapeutics is gearing up for Phase II and first-in-human trials in 2023 with its pipeline of precision medicines that offer safety and therapeutic advantages in cancer and immunology. The company's drug discovery approach focuses on developing candidates through clinical proof of concept, partnering those assets with companies to advance them through late-stage clinical development an..
Sirnaomics, a biopharmaceutical company focused on discovering and developing innovative drugs for indications with medical needs and large market opportunities, has announced the advancement of STP705 into late-stage clinical development for the treatment of Squamous Cell Carcinoma in situ (isSCC). The decision follows encouraging Phase IIa and Phase IIb clinical results that were shared with t..
The Department of Health – Abu Dhabi (DoH) has signed a Memorandum of Understanding with AbbVie Biopharmaceutical and M42 to advance personalised medicine and genomics in Abu Dhabi. The three parties aim to advance precision medicine in the diagnosis and treatment of multiple myeloma and non-small cell lung cancer. This strategic cooperation aims to maximise on the Emirate's unique genomics prog..
Avanos Medical, Inc. has announced an agreement to acquire Diros Technology Inc., a leading manufacturer of innovative radiofrequency (RF) products used to treat chronic pain conditions. The acquisition is expected to enhance Avanos' pain management treatment options and complement its premium COOLIEF* Cooled Radiofrequency product offering with the addition of Diros' unique RF Trident™ technolo..
